![Torsten Rüdiger Goesch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Torsten Rüdiger Goesch
Plus aucun poste en cours
Profil
Torsten Rüdiger Goesch is the founder of Vasodynamics Ltd. (founded in 2020).
He also held former positions as Chairman at Biosergen AB (2015-2024), Director at Rosetta Capital I LP, Managing Director at TRG Investors LLC (1999-2002), Director at STI Technologies Ltd., Director at Karolinska Development AB, Director at KDev Investments AB, Director at Cytochrome Ltd., Independent Director at Promore Pharma AB (2015-2024), Director at EyeSense GmbH, Director at.
Forward Pharma A (2006-2024), Director at Dilafor AB, Director at Pergamum AB, Director at KDev Oncology AB, Director at Modus Therapeutics AB, Independent Director at Modus Therapeutics Holding AB (2014-2024), Director at Vistagen Pte Ltd., and Director at Goesch Pharma Pte Ltd. He was also the General Manager-Central Europe at Biogen MA, Inc. (1997-1999) and Commercial Head at Merck Generics (1993-1995).
Dr. Goesch obtained a doctorate degree from Heinrich-Heine-Universität Düsseldorf and holds an MBA and a doctorate degree from Kellogg School of Management.
Anciens postes connus de Torsten Rüdiger Goesch
| Sociétés | Poste | Fin |
|---|---|---|
| FORWARD PHARMA A/S | Directeur/Membre du Conseil | 05/09/2024 |
Vistagen Pte Ltd.
 Vistagen Pte Ltd. MiscellaneousMiscellaneous Operates as a non-classified establishment | Directeur/Membre du Conseil | 05/09/2024 |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services Offers research and development services in the field of oncology | Directeur/Membre du Conseil | 05/09/2024 |
Rosetta Capital Ltd.
 Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital invests in early and mid-stage growth companies in biotechnology-related sectors. The firm invest in acquisition financing and spin-off transactions. | Private Equity Investor | 05/09/2024 |
Goesch Pharma Pte Ltd.
 Goesch Pharma Pte Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products | Directeur/Membre du Conseil | 05/09/2024 |
Formation de Torsten Rüdiger Goesch
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
48
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Develops and manufactures drugs related to immunology, neurobiology and oncology | Health Technology |
Rosetta Capital I LP | |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital invests in early and mid-stage growth companies in biotechnology-related sectors. The firm invest in acquisition financing and spin-off transactions. | Finance |
Heinrich-Heine-Universität Düsseldorf
 Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TRG Investors LLC
 TRG Investors LLC Investment ManagersFinance TRG Investors focuses on value-added asset management in underserved asset classes. The firm manages private investment funds using two strategies. The first strategy provides tactical asset allocation across all traditional asset classes, including domestic equities and fixed-income, international equities and fixed-income, real estate, currencies and commodities. The second strategy seeks to provide low correlation and high absolute returns by investing in small and micro-cap public companies and small private company buyouts with a geographical focus on the Upper Midwest. TRG Investors also invests alongside management in private equity transactions. They make both majority and minority investments and are willing to syndicate with other like-minded investors. The firm invests in profitable companies with solid growth potential that are led by exceptional management. TRG Investors primarily purchases equity in their private company investments, but will consider subordinated debt positions in certain situations. | Finance |
EyeSense GmbH
 EyeSense GmbH Electronic Equipment/InstrumentsElectronic Technology Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients | Electronic Technology |
Forward Pharma A/S
 Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Develops and manufactures proprietary formulations for inflammatory and neurological indications | Health Technology |
Sti Technologies Ltd.
 Sti Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Provides marketing solutions to the health care industry | Commercial Services |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Operates as a biotechnology company which develops antifungal drugs for the treatment of severe invasive fungal infections | Health Technology |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products from heparin derivatives | Health Technology |
Promore Pharma AB
 Promore Pharma AB BiotechnologyHealth Technology Develops therapeutic peptides for the bioactive would care market | Health Technology |
Merck Generics | |
Pergamum AB
 Pergamum AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products based on therapeutic peptides | Health Technology |
Karolinska Development AB
 Karolinska Development AB Financial ConglomeratesFinance Operates as a life sciences investment company | Finance |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services Offers research and development services in the field of oncology | Commercial Services |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drug for the treatment of severe malaria and sickle cell disease | Health Technology |
Modus Therapeutics Holding AB
 Modus Therapeutics Holding AB BiotechnologyHealth Technology Develops sevuparin to treat people suffering from sickle cell disease | Health Technology |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology Engages in research, sales, and development in the fields of medicine and owns and manages investments | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cytochrome Ltd. | |
Vistagen Pte Ltd.
Vistagen Pte Ltd. MiscellaneousMiscellaneous Operates as a non-classified establishment | Miscellaneous |
Goesch Pharma Pte Ltd.
Goesch Pharma Pte Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Biosergen AB
 Biosergen AB BiotechnologyHealth Technology Operates as a biotechnology company that develops antifungal drugs | Health Technology |
Vasodynamics Ltd.
 Vasodynamics Ltd. BiotechnologyHealth Technology Provides experimental development on biotechnology | Health Technology |
